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INTRODUCTION 
Carnitine deficiency related to epilepsy or an- 
tagonism of carnitine by antiepileptic drugs 
(AEDs) has attracted increasing attention since 
the first recognition of a neuromuscular de- 
ficiency syndrome in 1973’. Carnitine deficiency is 
linked to the potentially fatal hepatotoxicity that 
occasionally attends valproate therapy, particu- 
larly in children2, and has been documented in 
adult and pediatric patients taking valproate and 
other anticonvulsants3-9. The role of such de- 
ficiency in the lethargy, sedation, and cognitive 
disturbance that often attends chronic AED 
treatment is not clear”. We measured serum total 
and free carnitine levels in an ambulatory 
population of epilepsy patients well-controlled on 
valproate monotherapy or valproate plus a 
second medication, and without apparent hepatic 
or neuromuscular adverse effects from drug 
treatment. 
SUBJECTS AND METHODS 
Serum total and free carnitine was determined on 
77 occasions in 50 patients with partial and 
secondarily generalized or generalized seizures 
followed at the Ohio State University Epilepsy 
Center. Thirty patients were taking valproate 
monotherapy, while 45 were on polypharmacy 
with valproate plus carbamazepine (30), ethosux- 
imide (lo), or phenytoin (5). All patients had 
therapeutic levels of valproate, carbamazepine, 
ethosuximide, or phenytoin, and blood chem- 
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istries generally and live function tests particu- 
larly were within the normal range, as were serum 
creatine kinase levels. In addition to the over-the- 
counter medications, other medications taken at 
the time included tricyclic antidepressants for 
sleep disturbance or mood lability (6 patients), 
anti-inflammatory or vasoconstrictive medica; 
tions for vascular or tension headaches (5 
patients), antihistamines (4 patients), and oral 
contraceptives (29 patients). 
Thirty patients had partial seizures with secon- 
dary generalization or primarily generalized 
seizures, indicated by EEG-recorded seizures or 
bilaterally-synchronous epileptiform activity on 
interictal EEG, while 20 patients had partial 
seizures and focal slowing or epileptiform dis- 
charges on EEG. Thirty-four patients were 
female and 16 male, and ages ranged from 16 to 
50 years. Thirty-five patients had interictal 
behavioural symptoms involving ponderousness, 
stickiness, loquacity, and hypergraphia, although 
they had not previously received psychiatric 
diagnoses; 10 of these had consulted the counsel- 
ing services or support groups of the Epilepsy 
Association of Central Ohio due to emotional, 
situational, or family difficulties. Forty patients 
reported weakness, myalgia, fatigue, sleep distur- 
bances, or weakness. All patients had normal 
neurologic examinations, and cerebral structural 
lesions had been excluded during the previous 
evaluation of their epilepsy. No patients had 
known metabolic or nutritional disorders, none 
had dietary deficiencies or peculiarities, and none 
had known acute or chronic medical illnesses. 
Serum levels of total and free camitine were 
determined by a 14 C-Radioisotope enzymatic 
technique (Mayo Medical Laboratories, Roches- 
ter, MN, USA). Patient values were compared to 
the established normal range, which differs in 
1059-131 l/96/040251 + 03 $12.00/O 0 1996 British Epilepsy Association 
252 WE. Drake et a/ 
males (total camitine, 37-89 nmol/ml; free car- 
nitine, 28-69 nmol/ml) and females (total car- 
nitine, 30-73 nmol/ml; free carnitine, 19- 
60 nmol/ml). Carnitine levels in patients and 
controls, partial and generalized seizure patients, 
patients with and without interictal behavioural 
symptoms, and individuals with myalgic symp- 
toms and those without were compared by r-test. 
Chi-square was utilized to compare the incidence 
of abnormal carnitine levels in.age, gender, and 
seizure classification groups. 
RESULTS 
Serum carnitine levels are summarized in Table 1. 
Thirty-five per cent of patients had abnormally 
low free carnitine levels and 38.8% had abnor- 
mally low total camitine levels. Twenty-eight per 
cent of females and 41.7% of females had 
reduced free camitine, whilst 40% of females and 
37.5% of males had reduced total carnitine. The 
differences in hypocamitinemia were not sig- 
nificant when compared .by decade of age, gender 
or seizure type. Mean free and total carnitine 
levels were significantly lower among the seizure 
Table I: Comparison of carnitine levels in epilepsy patients 
and controls 
Epileptics Controls P value 
Total 
carnitine 
(nmol/ml) 
Free 
camitine 
(nmol/ml) 
Normal total 
carnitine 
Low total 
carnitine 
Normal free 
carnitine 
Low free 
carnitine 
Total 
camitine 
(nmol/ml) 
NS 
Total 
carnitine 
38.9 
(rtl3.7) 
30. I 
(k7.6) 
Males 
15 
10 
14 
IO 
Interictal 
behaviour 
symptoms 
35.5 
(*15.3) 
Fatigue & 
myalgia 
26.7 
(nmol/ml) (k16.5) 
48.5 
(*7.0) 
39.5 
(18.0) 
Females 
15 
10 
18 
8 
No symptoms 
41.9 
(*14.3) 
No symptoms 
42.8 
(zk8.5) 
co.01 
<O.Ol 
NS 
NS 
NS 
NS 
co.05 
patients than among controls, however (P < 
O.Ol), and generalized seizure patients had lower 
carnitine levels than those with partial seizures 
(P < 0.05). Patients taking valproate plus other 
medications had significantly lower carnitine 
levels (P ~0.01) but there was no correlation 
between carnitine and valproate levels. Patients 
with interictal disturbance of personality and 
behaviour had lower camitine levels than those 
not affected, but the difference was not sig- 
nificant, and the incidence of abnormally low 
carnitine levels was not significantly increased. 
Patients with fatigue, lassitude, myalgia, and 
similar complaints had lower carnitine levels than 
those without symptoms (P CO.05) and the 
incidence of abnormal carnitine levels was in- 
creased in this group (P < 0.01). No differences 
between total and free carnitine levels were noted 
in these groups. 
DISCUSSION 
These findings suggest that carnitine levels may 
be abnormally low in ambulatory adult epileptic 
patients taking valproate monotherapy or two- 
drug regimens including valproate with no evid- 
ence of hepatic dysfunction or myopathy. No 
significant differences were found with age of 
between sexes, nor was a clear difference evident 
between seizure types. Polypharmacy appeared 
to increase the likelihood of low camitine levels, 
and this was also more likely with fatigue and 
myalgia. Interictal personality and behaviour 
disturbance was associated to a lesser extent with 
low carnitine levels. 
Ohtani et af3 reported significant reduction in 
free and total camitine in 14 patients on valproate 
aged 3-21 years, although none of the patients 
were felt to be symptomatic. Most of these 
patients were taking polypharmacy or medica- 
tions in addition to valproate. Murphy and 
colleagues4 studied 13 children and found re- 
duced total carnitine levels, with abnormally low 
levels in 22% without specific symptoms. Laub 
and coworkers’ failed to find hypocarnitinemia in 
14 patients aged 3-21 taking valproate alone, and 
in fact found an increase in acylcarnitine levels, 
while seven patients taking valproate plus other 
drugs had a greater but not statistically significant 
decrease in carnitine levels. Melegh ef al6 showed 
significant reductions in free and total carnitine in 
11 children, some of whom had neurologic deficit 
and mental handicap. 
An appreciable number of adults and patients 
taking other AEDs were studied by Rodriguez- 
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Segade and colleagues’, and 76% of those taking 
valproate and 22% of those on other medications 
had low camitine levels, with significant reduction 
in mean levels overall. Many of these patients 
were apparently unaffected by hypocarnitenemia, 
although specific symptoms or lack thereof were 
not indicated. Beghi ef al.’ found carnitine 
deficiency in only 4% of patients taking valpro- 
ate, and found few adverse effects of deficiency 
and no correlation between carnitine levels and 
symptoms. A significant decrease in carnitine 
levels, apparently without symptoms, was found 
with polypharmacy including valproate, Coulter” 
found a marked and symptomatic reduction in 
carnitine levels in six children with cerebral palsy 
and other handicaps, who had multiple problems 
and were taking multiple medications. It has been 
suggested that carnitine deficiency may be more 
significant and more often symptomatic in pati- 
ents with underlying illnesses or neurological 
deficit complicating epilepsy than in those with 
seizures treated with valproate alone”. 
More common measurement of camitine levels 
during outpatient treatment of epilepsy with 
valproate or combination regimens may be 
appropriate. It may help to clarify some of the 
patient complaints regarding fatigue, lassitude, 
emotional disturbance, and altered cognition and 
energy which are common in the long-term 
management of seizures. 
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